BRPI0512705A - composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii - Google Patents

composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii

Info

Publication number
BRPI0512705A
BRPI0512705A BRPI0512705-0A BRPI0512705A BRPI0512705A BR PI0512705 A BRPI0512705 A BR PI0512705A BR PI0512705 A BRPI0512705 A BR PI0512705A BR PI0512705 A BRPI0512705 A BR PI0512705A
Authority
BR
Brazil
Prior art keywords
diabetes
dilipidemia
obesity
compound
treatment
Prior art date
Application number
BRPI0512705-0A
Other languages
English (en)
Inventor
Kurt Amrein
Daniel Hunziker
Alexandre Mayweg
Bernd Kuhn
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0512705A publication Critical patent/BRPI0512705A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO, PROCESSO DE PREPARAçãO DESTE E MéTODO PARA O TRATAMENTO E PROFILAXIA DE DIABETES, OBESIDADE, DISTúRBIOS ALIMENTARES, DILIPIDEMIA, HIPERTENSãO E DIABETES DO TIPO II Trata-se de compostos de fórmula (I), assim como sais e ésteres farmaceuticamente aceitáveis destes, onde R¬ 1¬ a R¬ 5¬ possuem o significado dado na reivindicação 1 que pode ser utilizado na forma de composições farmacêuticas.
BRPI0512705-0A 2004-06-28 2005-06-20 composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii BRPI0512705A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102999 2004-06-28
PCT/EP2005/006649 WO2006000371A2 (en) 2004-06-28 2005-06-20 Pyrimidine derivatives as 11beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0512705A true BRPI0512705A (pt) 2008-04-01

Family

ID=35478760

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512705-0A BRPI0512705A (pt) 2004-06-28 2005-06-20 composto, processo de preparação deste e método para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, dilipidemia, hipertensão e diabetes do tipo ii

Country Status (22)

Country Link
US (1) US7507733B2 (pt)
EP (1) EP1763517B1 (pt)
JP (1) JP4809339B2 (pt)
CN (1) CN1972918B (pt)
AR (1) AR049699A1 (pt)
AT (1) ATE509011T1 (pt)
AU (1) AU2005256442B2 (pt)
BR (1) BRPI0512705A (pt)
CA (1) CA2571361C (pt)
DK (1) DK1763517T3 (pt)
ES (1) ES2362884T3 (pt)
IL (1) IL179914A0 (pt)
MX (1) MXPA06014892A (pt)
MY (1) MY143568A (pt)
NO (1) NO20070445L (pt)
NZ (1) NZ551859A (pt)
PL (1) PL1763517T3 (pt)
PT (1) PT1763517E (pt)
RU (1) RU2375351C2 (pt)
TW (1) TWI299040B (pt)
WO (1) WO2006000371A2 (pt)
ZA (1) ZA200610415B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7632838B2 (en) * 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008005910A2 (en) * 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
NZ601483A (en) * 2008-08-04 2013-10-25 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201010975A (en) 2008-08-29 2010-03-16 Kowa Co 1-adamantylazetidin-2-one derivatives and drugs containing same
EP2348019A4 (en) 2008-10-29 2012-10-31 Kowa Co 1,2-DIAZETIDIN-3-ON DERIVATIVE AND PHARMACEUTICAL ACTIVE INGREDIENTS
CN102811620B (zh) 2010-01-25 2015-03-25 Chdi基金会股份有限公司 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
US20130310431A1 (en) * 2010-10-15 2013-11-21 Amgen Inc Uses for substituted 2-amino-thiazolones in treating alzheimer's disease
WO2012102366A1 (ja) * 2011-01-28 2012-08-02 日本たばこ産業株式会社 新規ピペラジン化合物の製造方法
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2017160922A1 (en) 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1229413A (pt) * 1967-06-14 1971-04-21
JP2744663B2 (ja) * 1988-12-29 1998-04-28 三井化学株式会社 ピリミジン類及びその薬学的に許容される塩類
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
TW287160B (pt) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
EP2399903A1 (en) * 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
MXPA06012130A (es) * 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.

Also Published As

Publication number Publication date
CA2571361A1 (en) 2006-01-05
WO2006000371A3 (en) 2006-04-27
CN1972918B (zh) 2010-10-13
NZ551859A (en) 2010-05-28
MY143568A (en) 2011-05-31
JP4809339B2 (ja) 2011-11-09
RU2007103303A (ru) 2008-08-10
IL179914A0 (en) 2007-05-15
ZA200610415B (en) 2008-06-25
ATE509011T1 (de) 2011-05-15
TWI299040B (en) 2008-07-21
AU2005256442B2 (en) 2009-02-12
AR049699A1 (es) 2006-08-30
AU2005256442A1 (en) 2006-01-05
NO20070445L (no) 2007-01-24
ES2362884T3 (es) 2011-07-14
US20050288308A1 (en) 2005-12-29
HK1104553A1 (zh) 2008-01-18
DK1763517T3 (da) 2011-06-06
JP2008504321A (ja) 2008-02-14
MXPA06014892A (es) 2007-02-28
EP1763517A2 (en) 2007-03-21
CA2571361C (en) 2011-07-26
CN1972918A (zh) 2007-05-30
PT1763517E (pt) 2011-07-01
US7507733B2 (en) 2009-03-24
EP1763517B1 (en) 2011-05-11
RU2375351C2 (ru) 2009-12-10
PL1763517T3 (pl) 2011-10-31
TW200616976A (en) 2006-06-01
WO2006000371A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
BR0307441A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
DK1915150T3 (da) Anvendelse af thienopyridinonderivater som AMPK-aktivatorer og farmaceutiske sammensætninger
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BR0212929A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
BRPI0513864A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
PA8531701A1 (es) Derivados de pirimidina
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
BR0308108A (pt) Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
WO2008011113A3 (en) Thiadiazolidinone derivatives
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
WO2007121389A3 (en) 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors
BRPI0516454A (pt) compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
BRPI0508392A (pt) materiais e métodos para tratar distúrbios de coagulação
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
TW200800993A (en) Organic compounds
BRPI0607645A2 (pt) sais de derivados de hexaidrofenantridina substituìdos com 6-heterociclila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.